Skip to main content
SpringerLink
Log in

Histamine dihydrochloride: a guide to its use in the management of acute myeloid leukaemia

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Yang LPH, Perry CM. Histamine dihydrochloride: in the management of acute myeloid leukaemia. Drugs 2011; 71(1): 109–22

    Article  PubMed  CAS  Google Scholar 

  2. Bubeník J. Interleukin-2 therapy of cancer. Folia Biol (Praha) 2004; 50(3–4): 120–30

    Google Scholar 

  3. Eklund JW, Kuzel TM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004 Nov; 16(6): 542–6

    Article  PubMed  CAS  Google Scholar 

  4. Blaise D, Attal M, Reiffers J, et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 2000 Mar; 11(1): 91–8

    PubMed  CAS  Google Scholar 

  5. Kolitz JE, Hars V, DeAngelo DJ, et al. Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients <60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808 [abstract no. 157]. Blood 2007 Nov 16; 110(11): e157

    Google Scholar 

  6. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Blood 2008 Feb 1; 111(3): 1044–53

    Article  PubMed  CAS  Google Scholar 

  7. Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 2008 Oct 20; 26(30): 4934–9

    Article  PubMed  CAS  Google Scholar 

  8. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010 Feb 10; 28(5): 808–14

    Article  PubMed  CAS  Google Scholar 

  9. Hellstrand K. Histamine in cancer immunotherapy: a preclinical background. Semin Oncol 2002 Jun; 29(3 Suppl. 7): 35–40

    Article  PubMed  CAS  Google Scholar 

  10. Romero AI, Thorén FB, Aurelius J, et al. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol 2009 Sep; 70(3): 194–205

    Article  PubMed  CAS  Google Scholar 

  11. Ceplene 0.5 mg/0.5 mL solution for injection: summary of product characteristics. London: European Medicines Agency, 2010

  12. Hellstrand K, Mellqvist U-H, Wallhult E, et al. Histamine and interleukin-2 in acute myelogenous leukemia. Leuk Lymphoma 1997 Nov; 27(5–6): 429–38

    PubMed  CAS  Google Scholar 

  13. Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol 1996 Mar; 92(3): 620–6

    Article  PubMed  CAS  Google Scholar 

  14. Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006 Jul 1; 108(1): 88–96

    Article  PubMed  CAS  Google Scholar 

  15. Buyse ME, Squifflet P, Allard SE, et al. Leukemia-free survival (LFS) as a surrogate for overall survival (OS) in AML patients in remission: a trial of a novel immunotherapy with histamine dihydrochloride plus low-dose IL-2 (HDC/IL-2) [abstract no. 0519]. Haematologica 2008 Jul; 93Suppl. 1: 209–10. Plus poster presented at the 13th Congress of the European Hematology Association; 2008 Jun 12–15; Copenhagen

    Google Scholar 

  16. Brune ML, Rowe JM, Szer J, et al. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML: long term follow-up of leukemia-free survival and overall survival [abstract no. 1846]. Blood 2007 Nov 16; 110(11): 1846. Plus poster presented at the American Society of Hematology 49th Annual Meeting and Exposition; 2007 Dec 8–11; Atlanta (GA)

    Google Scholar 

  17. Brune L, Rowe JM, Buyse ME, et al. Six-year outcomes update from a randomized phase 3 trial in AML: durable effect of remission maintenance immunotherapy with histamine dihydrochloride and low-dose IL-2 [abstract no. 0845]. Haematologica 2009 Jun; 94Suppl. 2: 340–1

    Google Scholar 

  18. Wallhult A, Whisnant K, Nilsson I, et al. Quality-of-life during remission maintenance immunotherapy in AML: a prospective assessment using EORTC QLQ-C30 in a randomized trial of histamine dihydrochloride plus low-dose IL-2 (HDC/IL-2) [abstract no. 0794]. Haematologica 2008 Jul; 93Suppl. 1: 316–7. Plus poster presented at the 13th Congress of the European Hematology Association; 2008 Jun 12–15; Copenhagen

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Histamine dihydrochloride: a guide to its use in the management of acute myeloid leukaemia. Drugs Ther. Perspect 27, 5–8 (2011). https://doi.org/10.1007/BF03257128

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03257128

Search

Navigation